Three questions to Elaine Jones, new Chair of BOOST Pharma

Elaine Jones, PhD brings decades of experience across biopharma, venture investing and board leadership, including senior roles at Pfizer Ventures and SR One, and service on more than 35 company boards. She joins BOOST Pharma at a pivotal moment as the company advances BT-101, its lead off-the-shelf cell therapy for osteogenesis imperfecta, toward Phase III development. 

You have spent your career backing and helping build innovative life science companies. What made you say yes to becoming Chair of BOOST Pharma?

What stood out to me about BOOST Pharma is the combination of compelling science, a very clear unmet medical need, and a team with the ambition and experience to build something important. BT-101 is an especially exciting program because the early clinical results suggest it has the potential to modify the disease of children living with osteogenesis imperfecta, a devastating disease where there are currently no approved disease-modifying therapies. Opportunities like these are rare, where breakthrough science and real patient impact come together, and that’s exactly the companies that I want to support.

You have worked with companies from seed stage through IPO and on both public and private boards. What do you hope to bring to BOOST in this next chapter?

I hope to bring a combination of strategic perspective, board leadership and practical experience in helping companies navigate inflection points. Over the years, I have worked with management teams and investors across company formation, financing, clinical development, partnering and public market transitions. At BOOST Pharma, that means helping the team stay focused on the highest-value priorities as BT-101 moves toward late-stage development, while also supporting the company in building the right partnerships, financing strategy and governance for long-term success.

As you look at BOOST today, what gives you the greatest confidence in the company’s future?

BOOST Pharma already has the ingredients that matter most: strong underlying science, encouraging clinical signals, a highly experienced leadership team, and a program with the potential to fundamentally change the treatment paradigm in osteogenesis imperfecta. This makes me confident in that BOOST is well positioned to create meaningful value for patients, partners and investors alike.